Conclusion
Our results show that luteolin protects against inflammation-induced
dopaminergic neuron loss. Mechanistically, luteolin deactivated TLR4
signaling in microglia, thus improving the inflammatory niche and
subsequently attenuating dopaminergic neuronal loss both in vivoand in vitro . Luteolin has limited adverse reactions and displays
low toxicity, and thus has broad application prospects as a PD
therapeutic.